Bio-Thera Solutions Ltd Class A 688177
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy
-
Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda® (Pembrolizumab)
-
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, a Proposed Biosimilar to Stelara® in the US and EU
Trading Information
- Previous Close Price
- ¥21.85
- Day Range
- ¥22.94–25.69
- 52-Week Range
- ¥18.00–47.46
- Bid/Ask
- ¥25.45 / ¥25.51
- Market Cap
- ¥10.56 Bil
- Volume/Avg
- 6.0 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,167
- Website
- https://www.bio-thera.com
Comparables
Valuation
|
Metric
|
688177
|
301207
|
688278
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.92 | 42.95 |
Price/Book Value | 10.82 | 2.11 | 14.47 |
Price/Sales | 13.37 | 5.45 | 12.19 |
Price/Cash Flow | — | 13.22 | 38.93 |
Price/Earnings
688177
301207
688278
Financial Strength
|
Metric
|
688177
|
301207
|
688278
|
|---|---|---|---|
Quick Ratio | 0.66 | 2.85 | 3.14 |
Current Ratio | 1.05 | 3.42 | 4.07 |
Interest Coverage | −22.79 | 149.96 | 1,553.17 |
Quick Ratio
688177
301207
688278
Profitability
|
Metric
|
688177
|
301207
|
688278
|
|---|---|---|---|
Return on Assets (Normalized) | −19.76% | 9.24% | 30.63% |
Return on Equity (Normalized) | −38.60% | 11.52% | 37.49% |
Return on Invested Capital (Normalized) | −26.78% | 10.82% | 37.06% |
Return on Assets
688177
301207
688278
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hrvpthvkg | Gpntm | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gdphkhmwj | Vkqyl | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mzswtjbzv | Nbkff | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lfcdspgj | Dcmwcbz | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Pbsztrqx | Tkvs | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qwwgfscn | Khg | $29.2 Bil | |||
| Moderna Inc
MRNA
| Rbbmssmp | Cnkv | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Sgqdvtbn | Pnjd | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wxzzgdz | Wwtwzp | $13.2 Bil | |||
| Incyte Corp
INCY
| Slcqcypyl | Lvtkwz | $13.0 Bil |
United States